

## eBox1. List of Medications with Potential Depression Adverse Effects Identified for Inclusion in Study (N=203)<sup>a</sup>

### A. Suicidal Symptoms (n=103)<sup>b</sup>

1. Analgesics (Acetaminophen/Tramadol, Hydroprmorphone, Tapentadol, Tramadol)
2. Anticonvulsants (Carbamazepine, Clonazepam, Diazepam, Ethosuximide, Gabapentin, Lamotrigine, Levetiracetam, Lorazepam, Methsuximide, Oxcarbazepine, Phenytoin, Pregabalin, Topiramate, Valproic Acid, Zonisamide)
3. Antidepressants (Amitriptyline, Amitriptyline/Chlordiazepoxide, Amitriptyline/Perphenazine, Bupropion, Citalopram, Clomipramine, Desipramine, Desvenlafaxine, Doxepin, Duloxetine, Escitalopram, Fluoxetine, Fluoxetine/Olanzapine, Fluvoxamine, Imipramine, Milnacipran, Mirtazapine, Nefazodone, Nortriptyline, Paroxetine, Phenelzine, Protriptyline, Selegiline, Sertraline, Trazodone, Venlafaxine, Vilazodone)
4. Anxiolytics, Hypnotics, and Sedatives (Alprazolam, Butabarbital, Chlordiazepoxide, Clonazepam, Clorazepate, Diazepam, Doxepin, Eszopiclone, Flurazepam, Pentobarbital, Ramelteon, Triazolam, Zaleplon, Zolpidem)
5. Gastrointestinal Agents (Metoclopramide)
6. Hormones/Hormone Modifiers (Finasteride<sup>1</sup>, Leuprolide, Levonorgestrel, Oxandrolone<sup>2</sup>, Progesterone)
7. Respiratory Agents (Montelukast, Ribavirin, Roflumilast, Zafirlukast<sup>3</sup>)
8. Other Therapeutic Classes (Acamprosate, Amantadine, Armodafinil, Aripiprazole, Asenapine, Atomoxetine, Carbidopa/Entacapone/Levodopa, Carbidopa/Levodopa, Ciprofloxacin, Dapsone, Efavirenz, Efavirenz/Emtricitabine/Tenofovir, Iloperidone, Interferon Beta-1a, Interferon Beta-1b, Isotretinoin, Lurasidone, Memantine, Mefloquine, Methylphenidate, Modafinil, Moxifloxacin, Naltrexone, Natalizumab, Olanzapine, Ofloxacin, Peginterferon Alfa-2a, Quetiapine, Raltegravir, Risperidone<sup>4</sup>, Rivastigmine<sup>5</sup>, Sibutramine, Tetrabenazine, Varenicline)

### B. Depressive (Non-Suicidal) Symptoms (n=100)<sup>c</sup>

1. Analgesics (Cyclobenzaprine, Fentanyl, Acetaminophen/Hydrocodone, Ibuprofen, Indomethacin, Morphine, Nabumetone, Oxycodone)
2. Antihypertensives (Atenolol, Atenolol/Chlorthalidone, Betaxolol, Bendroflumethiazide/Nadolol, Brimonidine, Brimonidine/Timolol, Dorzolamide/Timolol, Enalapril, Hydrochlorothiazide/Metoprolol, Hydrocodone, Metolazone, Metoprolol, Nisoldipine, Quinapril, Telmisartan, Timolol, Trandolapril)
3. Corticosteroids (Betamethasone, Cortisone, Dexamethasone, Methylprednisolone, Prednisolone, Prednisone, Triamcinolone)
4. Gastrointestinal Agents (Atropine/Diphenoxylate, Cimetidine, Dexlansoprazole, Esomeprazole, Famotidine, Omeprazole, Ranitidine)
5. Hormones/Hormone Modifiers (Anastrozole, Bicalutamide, Cabergoline, Conjugated Estrogens, Conjugated Estrogens/Medroxyprogesterone, Desogestrel/Ethinyl Estradiol, Dienogest/Estradiol, Drospirenone/Ethinyl Estradiol, Drospirenone/Ethinyl Estradiol/Levomefolate, Esterified Estrogens, Esterified Estrogens/Methyltestosterone, Estradiol, Estradiol/Norethindrone, Estropipate, Ethinyl Estradiol/Ethinodiol, Ethinyl Estradiol/Etonogestrel, Ethinyl Estradiol/Levonorgestrel, Ethinyl Estradiol/Norethindrone, Ethinyl Estradiol/Norgestimate, Ethinyl Estradiol/Norgestrel, Etonogestrel, Exemestane, Goserelin, Hydroxyprogesterone, Medroxyprogesterone, Megestrol, Norethindrone, Tamoxifen, Testosterone)
6. Respiratory Agents (Cetirizine<sup>6</sup>)
7. Other Therapeutic Classes (Abacavir/Lamivudine, Acebutolol, Acitretin, Amphetamine/Detroamphetamine, Baclofen, Benzphetamine, Cinacalcet, Clonidine, Cyclosporine, Dantrolene, Dexmethylphenidate, Donepezil, Dronabinol, Emtricitabine, Erlotinib, Flecainide, Fluphenazine<sup>7</sup>, Galantamine, Haloperidol, Maraviroc, Methylidopa, Metolazone, Metronidazole, Oxybutynin<sup>8</sup>, Phentermine<sup>9</sup>, Pimozide, Prazosin, Propafenone, Propranolol, Rasagiline, Rotigotine, Sorafenib, Tizanidine)

<sup>a</sup>Micromedex symptoms listed under the adverse effects section: depression, depressive disorder, suicide, suicidal thoughts, suicidal ideation, and suicidal behavior. Medications were not excluded if they had a mania side effect.

<sup>b</sup>Micromedex symptoms listed under the Adverse Effects section: suicide, suicidal thoughts, suicidal ideation, and suicidal behavior.

<sup>c</sup>Micromedex symptoms listed under the Adverse Effects section were considered "non-suicide" if they did not specify a suicide side effect. These included depression and depressive disorder.

<sup>1</sup> Depression adverse effect included on label. Suicide adverse effect cited in post-marketing article: Irwig, M. S. (2012). Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects. *The Journal of clinical psychiatry*, 73(9), 1220-1223. [https://www.ncbi.nlm.nih.gov/pubmed/22939118]

<sup>2</sup> Depression adverse effect included on label. Suicide adverse effect cited in post-marketing article: Pope HG & Katz DL: Affective and psychotic symptoms associated with anabolic steroid use. *Am J Psychiatry* 1988; 145:487-490.

<sup>3</sup> Depression adverse effect included on label. Suicide adverse effect cited post-marketing: US Food and Drug Administration: Updated Information on Leukotriene Inhibitors: Montelukast (marketed as Singulair), Zafirlukast (marketed as Accolate), and Zileuton (marketed as Zyflo and Zyflo CR). US Food and Drug Administration. Rockville, MD. 2009.

<sup>4</sup> Suicide adverse effect recorded on 2011 Risperdal label.

<sup>5</sup> Suicide adverse effect recorded on 2013 Exelon label.

<sup>6</sup> Depression adverse effect cited post-marketing article: Arendt C & Bernheim J: Double-blind comparison of maintenance treatment of chronic idiopathic urticaria by cetirizine and terfenadine. *Curr Ther Res* 1989; 46:724-734.

<sup>7</sup> Depression adverse effect cited in post-marketing article: Johnson, D. A. W. The side-effects of fluphenazine decanoate. *The British Journal of Psychiatry*, 1973; 123(576), 519-522.

<sup>8</sup> Depression adverse effect recorded on 2008 Ditropan XL label.

<sup>9</sup> Depression adverse effect cited in post-marketing articles: (1) Steel JM, Munro JF, & Duncan LJ: A comparative trial of different regimens of fenfluramine and phentermine in obesity. *Practitioner* 1973; 221:232-236. (2) Zoller B & Ruckert KH: Hemodynamic effects of the anorexic phentermine hydrochloride. *Munchen Med Wschr* 1973; 115:1244-1248.

Image courtesy of JAMA Network<sup>®</sup>

© 2018 American Medical Association